Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (MK-3475-921/KEYNOTE-921)

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2019
This article has no abstract
Epistemonikos ID: 2542bd3d0bad151db448f946297f52adebe69682
First added on: Apr 11, 2025